Table 3

The patterns of CEBPA mutations and immunophenotypes in the 16 AML patients

Patient
% Leukemic cells with the antigen expression*
NoFABCytogeneticsNH2-terminalCOOH-terminalHLA-DRCD34CD13CD33CD11bCD14CD15CD7CD56
2M2NTAD1-EbZIP -K948154000380ND
10M2NTAD1-GbZIP -G9936410006815ND
14M2NTAD1-FbZIP -J61685967ND0428ND
15M4NTAD1-HbZIP -B80145894232100530
16M1NTAD1-B, P1bZIP -E100419665121095980
18M2NTAD1-GbZIP -C100367593251295500
34M2nmTAD1-GbZIP -I100516410018262499ND
61M1sp, +21TAD1-GbZIP -E9863526284365448
69M2NTAD1-AbZIP -H100749551005590ND
91M1sp, del(9q)TAD1-IbZIP -A100100608224898853
93M1NTAD1-GbZIP -E10010080890075940
78M2sp, +8,+4TAD1-D, TAD2-ANND
23M2sp, +21NbZIP -D5824075009382ND
62M2NTAD1-CN242554ND29900
6M1NTAD1-BP491305450303560ND
52M1NNbZIP -F, -L9247488582926865
  • Abbreviations: N, normal karyotype or normal sequence; ND, not determined; nm, no metaphase; sp, simple (<4) chromosomal abnormalities excluding t(8;21), t(15;17), inv(16), aberrations at 11q23, −5/del(5q), −7/del(7q), and 3q abnormalities; +8, +4, +21, gain of the chromosome 8, 4, or 21.

  • * CD2, CD5, CD19, and CD10 were all negative in these patients.

  • The details of the mutations are shown in Table 1.

  • Homozygous for bZIP-D.